The Lead Episode 141: A Discussion of Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis

About this episode

This episode discusses the impact of GLP-1 receptor agonist therapy on atrial fibrillation recurrence in obese patients after catheter ablation.

Join Digital Education Committee member and podcast host Melissa E. Middeldorp, MPH, PhD, along with this week's guest contributors,Sheldon Litwin, MD from the Medical University of South Carolina and Abhishek Deshmuckh, MBBS from the Mayo Clinic for this week's episode. This real-world retrospective cohort study evaluated whether glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy is associated with improved outcomes after atrial fibrillation (AF) ablation in obese patients using a large multicenter electronic health record database (TriNetX). After propensity matching 6,700 patients (3,350 GLP-1RA users and 3,350 non-users), GLP-1RA therapy was associated with significantly lower AF recurrence, progression to permanent AF, cardiovascular and heart failure hospitalizations, and all-cause mortality over a median ~2-year follow-up, although repeat ablation rates were unchanged. The authors propose that benefits may be mediated through weight-loss, reduction in systemic inflammation and epicardial fat, improved metabolic control, and potential direct atrial effects, but emphasize that causal inference is limited due to observational design and lack of weight-loss trajectory…

People in this episode

Host: Melissa E. Middeldorp, MPH, PhD

Guests: Sheldon Litwin, MD, Abhishek Deshmuckh, MBBS

Topics covered

• GLP-1 receptor agonist therapy
• atrial fibrillation
• catheter ablation
• obesity
• real-world data analysis

Keywords

• GLP-1RA
• atrial fibrillation
• ablation
• obesity
• real-world study
• health outcomes
• cardiovascular hospitalization

Mentioned in this episode

Organizations: Medical University of South Carolina, Mayo Clinic

Products: glucagon-like peptide-1 receptor agonist (GLP-1RA)

More episodes of The Lead Podcast presented by Heart Rhythm Society

• The Lead Episode 155: A Discussion of A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation versus Anti-Arrhythmic Drug Therapy as a First Line Treatment for Persistent Atrial Fibrillation (AVANT GUARD) · June 11, 2026 · 22 min
• The Lead Episode 154: A Discussion of Safety and Effectiveness of a Dual-Energy Focal Ablation Catheter to Treat Paroxysmal Atrial Fibrillation: 6- Month Results of the FlexPulse IDE Study · June 4, 2026 · 26 min
• The Lead Episode 153: A Discussion of Exercise Capacity and Quality-of-Life Improvements after Catheter Ablation in Patients with Clinically Asymptomatic Persistent Atrial Fibrillation · May 28, 2026 · 18 min
• The Lead Episode 151: Heart Rhythm 2026 Late-Breaker Coverage: A Discussion of Outcomes of Left Atrial Appendage Closure versus Oral Anticoagulation in Patients with Atrial Fibrillation and Prior Ablation: A Sub-Analysis of the CHAMPION-AF Clinical Trial · May 21, 2026 · 33 min
• The Lead Episode 152: A Discussion of Outcomes of Left Atrial Appendage Closure versus Oral Anticoagulation in Patients with Atrial Fibrillation and Prior Ablation: A Sub-Analysis of the CHAMPION-AF Clinical Trial (New England Journal of Medicine) · May 21, 2026 · 22 min
• The Lead Episode 149: Heart Rhythm 2026 Late-Breaker Coverage: A Discussion of Safety and Performance of a Novel ICD Lead for Left Bundle Branch Area Pacing: Results from the ASCEND CSP Trial · May 14, 2026 · 15 min